![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() by Staff Writers Rio De Janeiro (AFP) Nov 10, 2020
Brazil's health regulator said Monday it had suspended clinical trials of a Chinese-developed Covid-19 vaccine after an "adverse incident" involving a volunteer recipient, a blow for one of the most advanced vaccine candidates. The setback for CoronaVac, developed by Chinese pharmaceutical firm Sinovac Biotech, came on the same day US pharmaceutical giant Pfizer said its own vaccine candidate had shown 90 percent effectiveness, sending global markets soaring and raising hopes of an end to the pandemic. The Brazilian regulator, Anvisa, said in a statement it had "ruled to interrupt the clinical study of the CoronaVac vaccine after a serious adverse incident" on October 29. It said it could not give details on what happened because of privacy regulations, but that such incidents included death, potentially fatal side effects, serious disability, hospitalization, birth defects and other "clinically significant events." However, the public health center coordinating the trials of the vaccine in Brazil, the Butantan Institute, said it was "surprised" by the decision. The institute "is investigating in detail what happened," and "is at the Brazilian regulatory agency's disposal to provide any clarification necessary on any adverse incident the clinical trials may have presented," it said. It said it would hold a press conference on Tuesday at 11:00 am (1400 GMT). CoronaVac has been caught up in a messy political battle in Brazil, where its most visible backer has been Sao Paulo Governor Joao Doria, a top opponent of far-right President Jair Bolsonaro. The Sao Paulo state government said in a statement it "regrets that it learned of the decision from the press, instead of directly from Anvisa," and was waiting along with the Butantan Institute for more information on "the real reasons for the suspension." - Pandemic politics - Bolsonaro has labeled CoronaVac the vaccine from "that other country," and pushed instead for a rival vaccine developed by Oxford University and pharmaceutical firm AstraZeneca. Last month, he shot down a plan by his own health minister to buy 46 million doses of CoronaVac, saying, "The Brazilian people will not be anyone's guinea pig," and referring to it as "Joao Doria's Chinese vaccine." Doria announced earlier Monday that the first 120,000 doses of CoronaVac would arrive in Sao Paulo on November 20. His state has a deal with Sinovac to buy a total of 46 million doses -- six million produced in China and the rest produced in Sao Paulo, which broke ground last week on a factory to make the vaccine domestically. "Officials in the state government fear Bolsonaro will use technical decisions to delay the timeline of the vaccine for political reasons," newspaper Folha de Sao Paulo reported, citing unnamed Doria allies. Anvisa told AFP it had no comment beyond its statement announcing the suspension, which said that halting trials was standard procedure in such cases. Bolsonaro faces criticism for his handling of the pandemic, which has included downplaying the virus, opposing lockdown measures and relentlessly promoting the drug hydroxychloroquine despite studies showing it is ineffective against Covid-19. The Sinovac, Pfizer and Oxford vaccines are all in Phase 3 trials, the final stage of testing before regulatory approval. All are being tested in Brazil, the country with the second-highest death toll in the pandemic after the United States, with more than 162,000 people killed by the new coronavirus. jhb/to
![]() ![]() WHO urged to invite Taiwan to key meeting Geneva (AFP) Nov 6, 2020 The World Health Organization is facing renewed pleas to allow Taiwan to participate in a key international meeting amid fears its exclusion could jeopardise efforts to rein in the coronavirus pandemic. As many parts of the world are reeling from surging numbers of Covid-19 infections and deaths, the WHO is due Monday to resume its main annual meeting, which was cut short in May. But while the World Health Assembly (WHA) is expected to focus heavily on international coordination of the pandemic ... read more
![]() |
|
The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us. |